Risk of T-cell Malignancy Following CAR T cells in Children, Adolescents and Young Adults
Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce, Rebecca A Gardner, Sara Ghorashian, Nirali N Shah, Shannon L.
Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce, Rebecca A Gardner, Sara Ghorashian, Nirali N Shah, Shannon L.
In a Chinese phase III trial, researchers found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved 2-year overall survival vs cisplatin/fluorouracil as part of definitive…
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
Brain and Other Nervous System Cancer statistics
Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients.
Halle Moore, MD, discusses some of the main concerns that patients with breast cancer have about fertility after treatment.
HRR testing is underused in patients with metastatic castration-resistant prostate cancer, a large study suggests.
Investigators examined the impact of a higher adiposity in childhood on tissue formation and the risk of breast cancer.
New guidance from the U.S. Preventive Services Task Force recommends women should get a mammogram every other year starting at age 40 and continuing until…
Relatlimab plus nivolumab and chemotherapy did not improve responses in untreated advanced gastric or GEJ cancer with a LAG-3 expression of at least 1%.
An abstract is unavailable.